CARVEDILOL, ivabradine hydrochloride - search results

northwind pharmaceuticals, llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 6.25 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see drug interactions ( 7.4) and clinical studies ( 14.1) ]. carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see clinical studies ( 14.2) ]. carvedilol tablets are indicated for the management of essential hypertension [ see clinical studies ( 14.3, 14.4)] . it can be used alone or in combination with other antihyper

Malta - English - Medicines Authority

carivalan 6.25mg/5mg film-coated tablets

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - carvedilol, ivabradine hydrochloride - film-coated tablet - carvedilol 6.25 mg ivabradine hydrochloride 5.390 mg - beta blocking agents

Malta - English - Medicines Authority

carivalan 6.25mg/7.5mg film-coated tablets

Malta - English - Medicines Authority

carivalan 12.5mg/5mg film-coated tablets

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - carvedilol, ivabradine hydrochloride - film-coated tablet - carvedilol 12.5 mg ivabradine hydrochloride 5.390 mg - beta blocking agents